Babesiosis is emerging as an important public health concern due to the potential severity of the infection, the apparent spread in geographic range, and the growing recognition that species other than Babesia microti cause infection in humans in the United States (12, 13, 18, 19) . While B. microti generally causes mild to moderately severe illness (9, 10, 16, 18) , severe and occasionally fatal infections with high levels of parasitemia have been reported, particularly among asplenic or immunosuppressed patients (3, 7, 13, 14) . The currently recommended therapy for B. microti and other Babesia infections, a 7-to 10-day course of clindamycin plus quinine, is based on its efficacy in laboratory animals (15, 21) and experience with individual patients (6, 22) . While this combination therapy does reduce parasitemia, it does not always eliminate the infection, and some patients experience recrudesences or persistent parasitemia (1, 19) . This problem is most common in immunosuppressed patients (3) and in those with other underlying medical conditions (7) .
Since the initial experimental trials with clindamycin and quinine, various new antimalarial and antiprotozoal drugs have been licensed for use in humans or are undergoing clinical trials and may be available for use in the near future. The purpose of this study was to evaluate several of these drugs for their activities against acute B. microti infections and for their ability to eliminate parasitemia completely.
MATERIALS AND METHODS
The Gray strain of B. microti, isolated from a patient in 1969 (5) and maintained at the Centers for Disease Control and Prevention since that time, was passaged in golden Syrian hamsters (Mesocricetus auratus). For the purpose of this study, parasitemias were determined by counting the number of infected erythrocytes (RBCs) in 200 RBCs in thin blood films stained with Giemsa. To monitor parasitemia, thin blood smears were prepared from a drop of blood collected from the tip of the tail. For inoculations of test animals, 1 cc or more of blood was collected by cardiac puncture from infected donor animals and the percentage of infected RBCs was determined with a drop of blood to prepare a thin smear. Blood was then diluted 1:5 with RPMI so that the volume to be inoculated could be more accurately measured. Experimental animals were inoculated intraperitoneally with approximately 10 7 B. microti-infected RBCs in a volume of 0.5 cc.
Drugs were chosen for screening based on one of two criteria. Several drugs currently in use as antimalarials, such as halofantrine, mefloquine, and the artesunate compounds, were selected, as these have not been tested against Babesia species. The other compounds were selected from the Walter Reed Army Institute of Research (WRAIR) screening system because of their demonstrated antiprotozoal activity. Several of these are already in phase I or II clinical trials. We arbitrarily chose not to screen compounds that were not likely to be in human trials in the near future, even if they had demonstrated antiparasitic activity. Drugs were obtained from WRAIR or by prescription from a local pharmacy. Drug treatments were initiated when parasitemia was between 3 and 7% (defined as day 0). All drugs were screened at the highest concentration and for the length of time deemed to be maximally effective yet safely tolerated. Drug efficacy, defined as the mean percent suppression of parasitemia compared with that in nontreated control animals, was assessed at 1, 3, and 7 days following the final treatment dose (posttreatment [PT]) for the preliminary screening studies and at 1, 3, 7, and 14 days PT for all subsequent evaluations. Routes of administration were dependent on each drug. Five animals per group were treated with each drug. For subcutaneous (s.c.) and intramuscular (i.m.) administration, the vehicle was peanut oil; for oral (p.o.) administration, the vehicle was hydroxyethylcellulose 0.5%-Tween 80 (HEC). Control animal groups (n ϭ 5 each) consisted of infected animals receiving either peanut oil, HEC, or no treatment.
Compounds screened for activity against B. microti included pentamidine isethionate; floxacrine (WR243251); [8-(6- 
benzaldehyde-4Ј-amidinophenylhydrazone dihydrochloride] (WR245720); artelenic acid (WR155663); halofantrine (WR171669); paromomycin; mefloquine (WR42490); artesunate (WR256283); pyrroloquinazoline (WR228275); a combination of clindamycin and quinine; biguanide (WR250417); and guanylhydrazone (WR249928).
Three compounds that showed the greatest activities in the initial trials, the two 8-aminoquinolines (WR006026 and WR238605) and a pyrroloquinazoline (WR228275), were further investigated to determine the minimum dose for * Corresponding author. Mailing address: Centers for Disease Control and Prevention, 4770 Buford Hwy., MS F-13, Atlanta, GA 30341. Phone: (770) 488-4419. Fax: (770) 488-4253. parasite clearance. Pentamidine isethionate and a combination of clindamycin plus quinine were included in these dosing studies for comparison purposes.
To determine if either of the two compounds (WR006026 and WR238605) that showed the most activity against B. microti during preliminary studies was capable of eliminating parasitemia (i.e., effecting a parasitologic cure), an additional study was conducted. Ten animals per group were used at each dose for this assessment, and animals with no parasitemia 14 days after the last drug dose were bled by cardiac puncture and 0.5 cc of blood was subpassaged intraperitoneally into naive animals. These animals were monitored weekly by thin blood smears for 6 weeks. Pentamidine isethionate and clindamycin plus quinine were included for comparison.
RESULTS
The results of the initial screening are shown in Table 1 . The compounds with the greatest percentage of suppression of parasitemia were the 8-aminoquinolines, WR0060260 and WR238605, both of which showed complete suppression of patent parasitemia at 3 and 7 days PT. Diamidine, pyrroloquinazoline, and biguanide all showed Ն95% suppression of parasitemia at 3 and 7 days PT, and artelenic acid suppressed parasitemia by 84% by 7 days PT. Conversely, pentamidine, floxacrine, mefloquine, halofantrine, artesunate, and guanylhydrazone exhibited no suppression of parasitemia by 7 days PT.
Both of the 8-aminoquinolines (WR006026 and WR238605) and the pyrroloquinazoline (WR228275) were reevaluated at lower doses (Table 2 ). WR006026 completely suppressed patent parasitemia at 3 and 7 days PT, at 3. quinazoline was less effective in the second trial than in the initial trial; the greatest reduction in parasitemia (76%) occurred at 7 days PT at 6 mg/kg b.i.d. times 3 days p.o. Both 8-aminoquinoline compounds suppressed parasitemia completely through day 14 PT; clindamycin plus quinine provided about 50% suppression on day 14, and pentamidine isethionate did not provide suppression of parasitemia after day 7 PT (Table 3) . When blood was subpassaged from the negative (8-aminoquinoline-treated) animals at day 14 PT, approximately half of the animals receiving blood from the group treated with WR006026 p.o. became parasitemic, but none of the animals receiving blood from the group treated with WR238605 i.m. developed parasitemia in the 6 weeks following subinoculation, indicating that parasitologic cure had been achieved.
DISCUSSION
Treatment of B. microti infections has always been problematic, and the need for a better drug has become increasingly urgent in recent years due to its spreading geographic range, the threat of infections in human immunodeficiency virus-AIDS patients, and an apparent increase in the number of infections in patients with other predisposing medical conditions. This situation is further complicated by the occurrence of human infections with species other than B. microti, which, in general, have been less responsive to conventional treatment with clindamycin and quinine. The inability to achieve parasitologic cures in patients infected with either B. microti or Babesia spp. heightens concerns over relapsing infections and the potential for subsequent transmission by blood donation and transfusion.
Because Babesia infections in older, splenectomized, and immunocompromised patients tend to be more severe with high levels of parasitemia, a drug is needed that rapidly reduces the level of parasitemia. Furthermore, because these individuals cannot rely on their immune systems to assist in the clearance of parasites, ideally therapy should permanently eliminate parasites from the blood.
Several of the drugs we tested showed rapid suppression and/or clearance of parasites from the blood of infected animals. Both 8-aminoquinolines reduced parasitemia by 88% by 24 h after the first dose and cleared parasitemia by day 3 after treatment, while pyrroloquinazoline, diamidine, and biguanide reduced parasitemia to Ͻ95% by day 3. In the dosing studies, WR006026 p.o. appeared to be slightly more effective at lower doses than did WR238605 i.m., although by day 7, animals receiving 3. were free of patent parasitemia following administration by either route. On the other hand, in the subpassage studies, blood drawn from animals that had received WR238605 i.m. did not result in infection in subpassaged animals, and thus the drug appeared to have effected a parasitologic cure. In contrast, blood drawn from about half of the animals that received WR006026 p.o. initiated infection when subpassaged, even though blood films were evaluated as negative. By comparison, in the same system, clindamycin plus quinine resulted in only about a 20% reduction in parasitemia on days 1 to 3 and a maximum reduction of between 70 and 90% by day 7 posttreatment. Since all animals in the clindamycin-plus-quinine treatment groups were still parasitemic at day 7, no subpassage experiments were undertaken.
We chose subpassage of blood as our preferred method to assess parasitological cure. Although this method might not be an absolute measure of parasitological cure, it is considered to be an extremely sensitive method for detecting low-level or subpatent B. microti parasitemia and is the method used by most investigators to detect such infections in humans. Splenectomy of the recipient animal does not increase its susceptibility to infection (4), and it is not clear that splenectomy or immunosuppression of treated animals provides any greater sensitivity than blood passage in determining a parasitological cure following treatment.
Inasmuch as several of the drugs we tested were considerably more effective than the currently accepted treatment, they would seem to hold great promise for further testing, particularly given the rapid clearance of patent parasitemia and continued suppression for up to 14 days of follow-up and subpassage of blood to clean animals. Two other drugs that have received attention in experimental studies are azithromycin and atovaquone. Azithromycin, either alone or in combination with quinine, was effective in reducing levels of parasitemia of B. microti in hamsters during the period of drug administration, but parasitemia rapidly returned to pretreatment levels when the drug was stopped (21) . Atovaquone, a 1,4-hydroxynaphthoquinone that has potent antimalarial activity and activity against Pneumocystis and Toxoplasma species, was somewhat more effective. Most experimentally infected hamsters survived infection and parasitemia never exceeded 1% in treated animals over 54 days of observation (8) . Based on our findings, the two 8-aminoquinolines tested in the present study show even greater activity against B. microti than either azithromycin or atovaquone.
As a class, the 8-aminoquinolines have marked activity against Babesia species. Primaquine phosphate and 4-methyl primaquine diphosphate (WR181023) were previously shown to be active against B. microti in the jird model (17) . The present study confirms that 8-aminoquinolines will be an effective class of compounds against Babesia organisms. Both WR238605 and WR006026 have been through phase I trials; WR006026 is currently undergoing phase II and III trials for use against Leishmania and Pneumocystis species, while phase 
